A New Treatment Could Help You Find Lasting Healing

If you’re struggling with a non-healing diabetic foot ulcer (DFU), learn more about a new, minimally invasive treatment option we offer. Unlike the surface cleanings and debridement you may be used to, this procedure targets the bony prominence that may be contributing to and worsening your wound — in just a single treatment.

Using a Tenex Health TX^® device equipped with advanced ultrasonic energy, we’re able to go under the surface and precisely remove scar tissue and the bony prominence, and enable a healthier environment for wound healing. The entire outpatient procedure, which uses mini incisions, takes just minutes under local anesthesia. It does not harm healthy soft tissue, and when done, doesn’t require stitches. It’s a revolutionary, single-procedure treatment option that gives you a better chance of getting back on your feet sooner and staying there.

A Single Procedure With Many Advantages

• Safe and minimally invasive
• Treats a root cause of recurrence
• Does not enter or expand the wound
• Skin grafts not required

Is a Procedure Using Tenex Health TX^® Right for You?

If your diabetic foot ulcer is considered chronic, you may be a good candidate for a procedure using Tenex Health TX^®.

Clinical Experience

Evidence shows that DFU procedures using Tenex Health TX^® are precise and highly effective at getting under

the surface to treat the primary contributing factor of recurrence, the bony prominence – all in a single treatment. In a retrospective case study of 105 DFU patients, all of whom had prior advanced wound care, 96% were healed with an average healing time of 3.5 weeks and with less than a 5% recurrence rate.¹

Individual results will vary.

Did you know?

• There’s a 40% – 80% infection rate for DFUs²
• Recurrence rates are as high as 65%³
• Over 25% of patients may require amputation⁴

To schedule a consultation:

The Southside Foot Clinic

33 E County Line Rd, Suite B
Greenwood, IN 46143

Phone: (317) 882-9303

References:

1. Freed Diabetes 2020 Jun;69(Supplement 1).
2. Geraghty T, LaPorta Expert Rev Pharmacoecon Outcomes Res 2019.
3. Armstrong DG, et al. N Engl J Med
4. Kim S, et Vasc Spec Int 2018.

Patient-Newsletter-Template-DFU-MKT-394RevA